DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
TEPRASIRAN
Search structure
Synonyms:
I5-NP
I5NP
Qpi-1002
QPI-1002
Teprasiran
Status:
Phase 3
Entry Type:
Oligonucleotide
Molecule Category:
UNKNOWN
UNII:
O03W5S19PJ
Pharmacology
Action
Mechanism of Action
Reference
RNAI INHIBITOR
p53 mRNA RNAi inhibitor
PubMed
EMA
Indications
Mesh Heading
Maximum Phase
Mesh ID
Reference
Acute Kidney Injury
2
D058186
ClinicalTrials
Cross References
Resources
Reference
ChEMBL
CHEMBL4297574
FDA SRS
O03W5S19PJ
CONTENTS
Structure
Indications
Cross References
×
Active Pharmaceutical Ingredients (APIs)
Scaffolds
Exact
Similarity
SubStructure
Threshold (%) >=
70